GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc.

GEHCNYSE / NASDAQHealthcareLarge cap

$80.64-$1.25 (-1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$29.0B
P/E
13.9x
EV / EBITDA
9.2x
Revenue
$20.6B
Net margin
10.1%
ROCE
9.9%

+7.9% over the last year

GE HealthCare Technologies Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+14.8%
3M
+8.9%
6M
+25.5%
1Y
+7.9%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$1.25 (-1.5%) from $82 to $81 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GEHC, bought on each weekday since 2022.

News & filings

What GE HealthCare Technologies filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernNet margin of 10.1% against a peer median of 15.5%.

Strengths (1)

  • Return on equity of 20.1% against a peer median of 14.0%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

Read moreShow less

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Sector
Healthcare
Shares outstanding
457.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$29.0B
P/E
13.9x
P/B
2.8x
EV / EBITDA
9.2x
EV / Sales
1.7x
P/S
1.4x
52-week high
$88.16
52-week low
$59.49

Profitability

Operating margin
13.4%
Net margin
10.1%
EBITDA margin
18.4%
ROE
20.1%
ROCE
9.9%
ROA
5.6%
Asset turnover
0.56

Growth

Revenue
$20.6B
Revenue growth, 1Y
4.8%
Revenue CAGR, 3Y
4.0%
Net profit growth, 1Y
4.6%
Free cash flow
$1.5B

Solvency

Current ratio
1.37
Debt / Equity
1.01
Debt / Assets
0.28
CFO / Net profit
0.95
Cash / Market cap
15.5%

Where the revenue went

Of every $100 of FY2025 revenue, $10 was left as net income.

GE HealthCare Technologies Inc. income statement flow, FY2025
GE HealthCare Technologies Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$12.4B
RevenueGross profit$8.2B
Gross profitResearch and development$1.3B
Gross profitSelling, general and administrative$4.2B
Gross profitOperating income$2.8B
Operating incomePretax income$2.8B
Interest and other incomePretax income$6.0M
Pretax incomeTax and other$684.0M
Pretax incomeNet income$2.1B

Revenue and net profit

Revenue grew 4.8% in FY2025; net profit is the dashed line.

GE HealthCare Technologies Inc. revenue and net profit by fiscal year
GE HealthCare Technologies Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$18.3B$1.9B
FY2023$19.6B$1.6B
FY2024$19.7B$2.0B
FY2025$20.6B$2.1B

Cash flows

FY2025: $2.0B from operations, $1.5B free after investment (dashed).

GE HealthCare Technologies Inc. operating and free cash flow by fiscal year
GE HealthCare Technologies Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$2.1B$1.8B
FY2023$2.1B$1.7B
FY2024$2.0B$1.6B
FY2025$2.0B$1.5B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$20.6B+4.8%1Y
EBITDA
$3.8B+3.3%1Y
Net profit
$2.1B+4.6%1Y
Cash from operations
$2.0B+1.8%1Y
Free cash flow
$1.5B-2.9%1Y
Revenue CAGR, 3Y
4.0%
Net profit CAGR, 3Y
2.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$20.6B$3.8B$2.1B$1.5B20.1%+4.8%+4.6%

Monthly returns

Month-by-month returns of GEHC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$36.9B
Liabilities$26.3B
Equity$10.6B
Paid-in capital$6.7B
Retained earnings$5.3B
Treasury stock$225.0M
Minority interest$220.0M

Market cap against peers

8 peers: same sector, nearest by size.

  1. GE HealthCare Technologies Inc. (this company)$29.0B

Peers map

Healthcare companies placed by value, growth and quality; GEHC highlighted.

P/E against peers

GEHC trades at 13.9x earnings against a peer median of 21.3x (a 35% discount).

  1. GE HealthCare Technologies Inc. (this company)13.9x

Not shown (no positive earnings and no EV / Sales): Centene Corporation, Insmed Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
GE HealthCare Technologies Inc.GEHCthis companyP/E ↓ discount$29.0B13.9x2.8x20.1%9.2x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
Biogen Inc.BIIB$29.0B22.4x1.6x7.1%12.5x
ResMed Inc.RMD$28.2B20.1x4.7x23.5%14.5x
DexCom, Inc.DXCM$28.0B33.5x10.2x30.5%21.0x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
Peer median—21.3x4.8x14.0%13.0x

Year-to-date ROI

GEHC since 1 January, against earlier years.

Historical volatility

GEHC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

GE HealthCare Technologies Inc. operating margin by fiscal year
GE HealthCare Technologies Inc. operating margin by fiscal year
DateOperating margin
FY202213.8%
FY202312.5%
FY202413.3%
FY202513.4%
LineFY2025
Cost of revenueCost Of Revenue$12.4B
Gross profitGross Profit$8.2B
Operating expensesOperating Expense$5.5B
Research and developmentResearch And Development$1.3B
Selling, general and administrativeSelling General And Administration$4.2B
Total expensesTotal Expenses$17.9B
Pretax incomePretax Income$2.8B

Learn while you research

Academy chapters picked for GE HealthCare Technologies Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →